Good Practice Guidelines for the Use of Statistical Regression Models in Economic Evaluations
Overview
Authors
Affiliations
Decision-analytic models (DAMs) used to evaluate the cost effectiveness of interventions are pivotal sources of evidence used in economic evaluations. Parameter estimates used in the DAMs are often based on the results of a regression analysis, but there is little guidance relating to these. This study had two objectives. The first was to identify the frequency of use of regression models in economic evaluations, the parameters they inform, and the amount of information reported to describe and support the analyses. The second objective was to provide guidance to improve practice in this area, based on the review. The review concentrated on a random sample of economic evaluations submitted to the UK National Institute for Health and Clinical Excellence (NICE) as part of its technology appraisal process. Based on these findings, recommendations for good practice were drafted, together with a checklist for critiquing reporting standards in this area. Based on the results of this review, statistical regression models are in widespread use in DAMs used to support economic evaluations, yet reporting of basic information, such as the sample size used and measures of uncertainty, is limited. Recommendations were formed about how reporting standards could be improved to better meet the needs of decision makers. These recommendations are summarised in a checklist, which may be used by both those conducting regression analyses and those critiquing them, to identify what should be reported when using the results of a regression analysis within a DAM.
Feng J, Zhang K, Dou L, Shi Z, Chen G, Li S Qual Life Res. 2024; 33(9):2321-2334.
PMID: 38824212 DOI: 10.1007/s11136-024-03670-8.
Shah R, Salek M, Finlay A, Kay R, Nixon S, Otwombe K Qual Life Res. 2024; 33(4):1107-1119.
PMID: 38402530 PMC: 10973087. DOI: 10.1007/s11136-023-03590-z.
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.
Otten T, Grimm S, Ramaekers B, Joore M Pharmacoeconomics. 2023; 41(6):619-632.
PMID: 36943674 PMC: 10163110. DOI: 10.1007/s40273-023-01242-1.
Binuya M, Engelhardt E, Schats W, Schmidt M, Steyerberg E BMC Med Res Methodol. 2022; 22(1):316.
PMID: 36510134 PMC: 9742671. DOI: 10.1186/s12874-022-01801-8.
Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L.
Aghdaee M, Gu Y, Sinha K, Parkinson B, Sharma R, Cutler H Pharmacoeconomics. 2022; 41(2):187-198.
PMID: 36336773 PMC: 9883346. DOI: 10.1007/s40273-022-01157-3.